Insider Transactions Reported by 14 Insiders of Atea Pharmaceuticals, Inc.

Symbol
AVIR on Nasdaq
Location
Boston, MA

Insiders trading volume in the past year

Atea Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Jean-Pierre Sommadossi President, CEO, and Chairman, Director $19,175,438 31 Jan 2025
Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal and Secretary $2,227,089 31 Jan 2025
FRANKLIN BERGER Director $1,597,328 +$81,499 +5.4% 20 Jun 2025
John Vavricka Chief Commercial Officer $438,617 31 Jan 2025
Bruno Lucidi Director $435,774 20 Jun 2025
Bruce Polsky Director $399,257 20 Jun 2025
Polly A. Murphy Director $372,232 20 Jun 2025
Jerome M. Adams Director $288,274 20 Jun 2025
Barbara Gayle Duncan Director $288,274 20 Jun 2025
Janet Hammond Chief Development Officer $283,472 31 Jan 2025
Maria Arantxa Horga Chief Medical Officer $216,116 31 Jan 2025
Wayne Foster EVP, Chief Accounting Officer $180,283 31 Jan 2025
ARTHUR S. KIRSCH Director $139,873 20 Feb 2025
Howard Berman Director 20 Jun 2025

Recent Insider Transactions by Companies or Individuals for Atea Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.